Authors
Latest:
Apatinib/Chemotherapy Demonstrates Encouraging Efficacy, Tolerability in Advanced SCLCIn pretreated patients with advanced small cell lung cancer, treatment with the combination of apatinib and single-agent chemotherapy showed promising efficacy and was well-tolerated, data from a prospective phase 2 study.
Latest:
Providing Predictive and Prognostic Biomarkers for Breast Cancer From the TAILORx TrialJesus Anampa, MD, MS, assistant professor, Department of Medicine, Albert Einstein School of Medicine, says in the past, most patients with breast cancer were treated with chemotherapy. In some cases, these patients were being over-treated. To limit the use of chemotherapy in patients who don’t need it, a group of researchers conducted the TAILORx trial.
Latest:
Considerations When Selecting Patients With R/R Myeloma for Cilta-Cel TreatmentJesus Berdeja, MD, shares factors oncologists in the community should consider when referring patients for chimeric antigen receptorT-cell therapy with the newly approved agent ciltacabtagene autoleucel.
Latest:
CAR T Cells Have Potential as Earlier-Line Therapy for Multiple MyelomaJesus G. Berdeja, MD, discusses the potential of chimeric antigen receptor T-cell therapy to be approved for earlier lines of treatment in multiple myeloma.
Latest:
Dr. Jimmie Holland on the Evolution of Genomic Medicine in OncologyJimmie Holland, MD, Wayne E. Chapman Chair in Psychiatric Oncology, Memorial Sloan Kettering Cancer Center, on the development of genomic medicine in oncology.
Latest:
The Oncology Drug Development ProcessJo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute, discusses the FDA approval process for oncology drugs.
Latest:
Joan Lunden Discusses Her TNBC DiagnosisJoan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.
Latest:
Dr. Joanne Blum on the Function of Talazoparib in Locally Advanced and/or Metastatic Breast CancerJoanne Blum, MD, PhD, discusses the function of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer.
Latest:
Fulvestrant Plus Palbociclib in Breast CancerJoanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the combination of fulvestrant and palbociclib (Ibrance) in patients with breast cancer, as well as the synergy fulvestrant has with other CDK4/6 inhibitors.
Latest:
Managing Adverse Events Associated With Immunotherapy in Bladder CancerJoaquim Bellmunt, MD, PhD, shares his recommendation in how to manage the side effects of immunotherapy as a monotherapy, particularly PD-1/PD-L1, in patients with bladder cancer.
Latest:
Dr. Joe O'Sullivan on Utilizing Radium-223 Treatment Earlier in Patients With mCRPCJoe O'Sullivan, MD, on utilizing radium-223 treatment earlier in patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest:
The Importance of Testing for BRAF Status in CRC PatientsJohanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the importance of testing CRC patients for BRAF status.
Latest:
Using Immunotherapies to Treat Patients With Colorectal CancerJohanna C. Bendell, MD, director of GI Oncology Research at Sarah Cannon Research Institute, discusses using immunotherapy for the treatment of patients with colorectal cancer.
Latest:
Acalabrutinib Shows Higher Tolerability Versus Ibrutinib in CLLJohn C. Byrd, MD, discusses the early results and adverse events observed in the ELEVATE-RR trial in patients with chronic lymphocytic leukemia.
Latest:
Role of Ruxolitinib in GVHD TreatmentDrs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.
Latest:
Fulvestrant as First-Line Treatment for Advanced Breast CancerJohn F. R. Robertson, MD, discusses overall survival data from the phase II FIRST study, which looked at fulvestrant as first-line therapy for patients with advanced breast cancer.
Latest:
Acalabrutinib Shows Better Exposure-Adjusted Tolerability in R/R CLLJohn F. Seymour, MBBS, PhD, discusses the results of a post-hoc analysis of adverse events in the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Latest:
Dr. John H. Sampson on the Use of Rindopepimut in Brain CancerDr. John H. Sampson discusses rindopepimut elimiting brain tumor cells that express the epidermal growth factor receptor mutation variant III (EGFRvIII).
Latest:
Assessing the Role of 21-Gene Assays in Breast CancerJohn H. Ward, MD, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.
Latest:
Dr. John Hays on Gynecologic Cancer Mutations and Choosing the Right TreatmentHays says current genetic testing gives oncologists a wide variety of information that may make choosing the correct treatment "a little more difficult." Hays adds that within the current treatment paradigm of gynecologic cancer, oncologists are mainly focusing on BRCA mutations.
Latest:
The Role of HER2-Targeted Therapy for Gastric CancerJohn L. Marshall, MD, discusses the situations where patients could benefit from fam-trastuzumab deruxtecan-nxki as second-line treatment for locally advanced or metastatic HER2-positive gastric cancer.
Latest:
Dr. John Leonard on Treatment Options in Follicular LymphomaJohn Leonard, MD, discusses the number of options doctors have to choose from when treating follicular lymphomas.
Latest:
Exploring Potential Curative Therapies for Diffuse Large B-Cell LymphomaJohn M. Pagel, MD, PhD, discusses the current setting of diffuse large B-cell lymphoma and some of the treatments available at the moment.
Latest:
Recent Advances and Future Directions in the Management of HER2+ Gastric CancerAn expert in gastric cancers provides insight on the recent advances and future directions for the management of locally advanced and metastatic gastric cancers.
